# Bio-significance of LPC16:0 in Fibromyalgia

> **NCT04832100** · — · RECRUITING · sponsor: **Kaohsiung Medical University Chung-Ho Memorial Hospital** · enrollment: 245 (estimated)

## Conditions studied

- Fibromyalgia, Primary
- Pain
- Soreness, Muscle
- Oxidative Stress
- Metabolomics
- Lipidomics

## Interventions

- **DRUG:** Pregabalin 150mg, imipramine 25mg

## Key facts

- **NCT ID:** NCT04832100
- **Lead sponsor:** Kaohsiung Medical University Chung-Ho Memorial Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2021-06-01
- **Primary completion:** 2026-06-30
- **Final completion:** 2027-06-30
- **Target enrollment:** 245 (ESTIMATED)
- **Last updated:** 2025-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04832100

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04832100, "Bio-significance of LPC16:0 in Fibromyalgia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04832100. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*